Philo­gen who? A low pro­file but phar­ma-con­nect­ed Ital­ian-Swiss hy­brid steps out with $68M for a fi­nal push over the PhI­II fin­ish line

Philo­gen is one of the best con­nect­ed late-stage biotechs you’ve prob­a­bly nev­er heard of. 

Found­ed by three broth­ers — the busi­ness­man and com­pa­ny CEO Duc­cio Neri and his two sci­en­tist sib­lings, Dario and Gio­van­ni — way back in 1996, Philo­gen has been build­ing up its ex­per­tise in armed an­ti­bod­ies over the past 23 years. It’s struck mul­ti­ple de­vel­op­ment pacts with a whole range of phar­ma gi­ants, oc­ca­sion­al­ly rather ca­su­al­ly and briefly not­ing them in ab­bre­vi­at­ed re­leas­es — like the three it an­nounced in Jan­u­ary with No­var­tis, J&J and Cel­gene, shorn of any specifics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.